A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

NCT07650084 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Chronic Cough

Interventions

DRUG: BLU-5937
DRUG: Placebo

Sponsor

GlaxoSmithKline